Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:ERAS NASDAQ:ESPR NASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$32.09+2.0%$27.21$15.35▼$36.44$3.31B2.262.01 million shs227,506 shsERASErasca$10.24-1.6%$15.68$1.06▼$24.28$3.24B0.687.24 million shs742,056 shsESPREsperion Therapeutics$3.15+0.2%$2.53$0.69▼$4.18$809.54M0.918.57 million shs2.29 million shsORKAOruka Therapeutics$64.18+0.2%$51.60$8.91▼$91.00$3.23B-0.21.03 million shs228,618 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-2.55%+3.76%+28.50%+18.67%+93.90%ERASErasca-4.59%-2.35%-39.04%-15.38%+748.98%ESPREsperion Therapeutics-0.32%+57.00%+35.93%-7.65%+260.92%ORKAOruka Therapeutics-8.20%-6.34%+5.73%+93.86%+573.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$32.09+2.0%$27.21$15.35▼$36.44$3.31B2.262.01 million shs227,506 shsERASErasca$10.24-1.6%$15.68$1.06▼$24.28$3.24B0.687.24 million shs742,056 shsESPREsperion Therapeutics$3.15+0.2%$2.53$0.69▼$4.18$809.54M0.918.57 million shs2.29 million shsORKAOruka Therapeutics$64.18+0.2%$51.60$8.91▼$91.00$3.23B-0.21.03 million shs228,618 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-2.55%+3.76%+28.50%+18.67%+93.90%ERASErasca-4.59%-2.35%-39.04%-15.38%+748.98%ESPREsperion Therapeutics-0.32%+57.00%+35.93%-7.65%+260.92%ORKAOruka Therapeutics-8.20%-6.34%+5.73%+93.86%+573.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.71Moderate Buy$47.1746.97% UpsideERASErasca 2.50Moderate Buy$17.8874.59% UpsideESPREsperion Therapeutics 2.00Hold$5.5476.15% UpsideORKAOruka Therapeutics 2.82Moderate Buy$120.8088.23% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, BEAM, ORKA, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026ESPREsperion Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/1/2026ESPREsperion Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.164/30/2026ORKAOruka Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$120.004/29/2026ORKAOruka Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $120.004/28/2026ORKAOruka Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$75.00 ➝ $100.004/27/2026ORKAOruka Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$165.004/27/2026ORKAOruka Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$78.00 ➝ $160.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$139.74M23.60N/AN/A$12.20 per share2.63ERASErascaN/AN/AN/AN/A$1.05 per shareN/AESPREsperion Therapeutics$403.14M2.01N/AN/A($1.26) per share-2.50ORKAOruka TherapeuticsN/AN/AN/AN/A$9.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$79.99M-$1.01N/AN/AN/A-57.24%-30.65%-23.73%N/AERASErasca-$124.55M-$0.44N/AN/AN/AN/A-34.48%-28.74%5/12/2026 (Estimated)ESPREsperion Therapeutics-$22.68M-$0.17N/A14.302.56-3.66%N/A-3.93%N/AORKAOruka Therapeutics-$105.43M-$1.86N/AN/AN/AN/A-25.48%-24.34%5/13/2026 (Estimated)Latest ESPR, BEAM, ORKA, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ORKAOruka Therapeutics-$0.52N/AN/AN/AN/AN/A5/12/2026Q1 2026ERASErasca-$0.19N/AN/AN/AN/AN/A5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million3/12/2026Q4 2025ERASErasca-$0.11-$0.10+$0.01-$0.10N/AN/A3/12/2026Q4 2025ORKAOruka Therapeutics-$0.61-$0.45+$0.16-$0.45N/AN/A3/10/2026Q4 2025ESPREsperion Therapeutics$0.23$0.22-$0.01$0.22$165.12 million$168.45 million2/24/2026Q4 2025BEAMBeam Therapeutics-$1.13$2.33+$3.46$2.33$13.22 million$114.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A13.0913.09ERASErascaN/A10.0410.04ESPREsperion TherapeuticsN/A1.541.19ORKAOruka TherapeuticsN/A22.3722.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%ERASErasca67.78%ESPREsperion Therapeutics47.39%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.80%ERASErasca14.40%ESPREsperion Therapeutics1.70%ORKAOruka Therapeutics23.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510102.75 million98.84 millionOptionableERASErasca120310.97 million266.19 millionOptionableESPREsperion Therapeutics200257.41 million253.03 millionOptionableORKAOruka TherapeuticsN/A50.20 million38.41 millionN/AESPR, BEAM, ORKA, and ERAS HeadlinesRecent News About These CompaniesOruka Therapeutics (ORKA) slides 8.2% as investors digest recent $700M equity raiseMay 7 at 5:30 PM | quiverquant.comQHalozyme and Oruka sign agreement for Hypercon technologyMay 7 at 7:24 AM | pharmaceutical-technology.comPHalozyme Therapeutics, Inc.: Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon TechnologyMay 6 at 11:22 AM | finanznachrichten.deHalozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyMay 6 at 8:00 AM | prnewswire.comOruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on WednesdayMay 6 at 7:36 AM | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Trading Down 5.9% - Here's WhyMay 1, 2026 | marketbeat.comQ2 EPS Estimate for Oruka Therapeutics Boosted by AnalystMay 1, 2026 | marketbeat.comOruka Therapeutics prices upsized $700M public offering at $72.50 per shareApril 30, 2026 | msn.comOruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001April 30, 2026 | finance.yahoo.comStifel Nicolaus Keeps Their Buy Rating on Oruka Therapeutics (ORKA)April 30, 2026 | theglobeandmail.com5 Small-Cap Stocks That Are On Fire Right NowApril 30, 2026 | insidermonkey.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Up 22.4% in AprilApril 30, 2026 | marketbeat.comOruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque Psoriasis - SlideshowApril 29, 2026 | seekingalpha.comOruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading Volume - Time to Buy?April 29, 2026 | marketbeat.comMoody Aldrich Partners LLC Takes $3.84 Million Position in Oruka Therapeutics, Inc. $ORKAApril 29, 2026 | marketbeat.comOruka surges as long-acting psoriasis drug shows early promiseApril 29, 2026 | biopharmadive.comBOruka reports positive data from Phase IIa trial for plaque psoriasisApril 29, 2026 | yahoo.comOruka Therapeutics (ORKA) price target increased by 34.40% to 91.96April 29, 2026 | msn.comOruka Therapeutics, Inc. Prices Upsized Public Offering of 9.66 Million Shares at $72.50 Per ShareApril 28, 2026 | quiverquant.comQOruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public OfferingApril 28, 2026 | globenewswire.comOruka Therapeutics (NASDAQ:ORKA) Trading 6.6% Higher - What's Next?April 28, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026ESPR, BEAM, ORKA, and ERAS Company DescriptionsBeam Therapeutics NASDAQ:BEAM$32.09 +0.62 (+1.98%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Erasca NASDAQ:ERAS$10.24 -0.16 (-1.56%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Esperion Therapeutics NASDAQ:ESPR$3.14 +0.01 (+0.16%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Oruka Therapeutics NASDAQ:ORKA$64.18 +0.11 (+0.17%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
